Sanguine Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Private

  • Employees
  • 139

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 20

Sanguine General Information

Description

Developer of personalized medicines intended to bridge the gap between patients and researchers. The company provides tools and concierge services that empower patients to participate in research from home and deliver transparency throughout the research process, enabling patients to participate in medical research and have a direct impact on the development of new treatments.

Contact Information

Website
www.sanguinebio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Technology Systems
Other Industries
Biotechnology
Other Healthcare Services
Drug Discovery
Primary Office
  • 400 West Cummings Park
  • Suite 3050
  • Woburn, MA 01801
  • United States
+1 (855) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Sanguine Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 09-Jan-2023 00.000 Completed Generating Revenue
7. Secondary Transaction - Private 00.000 Completed Generating Revenue
6. Debt - PPP 08-Apr-2020 00.000 Completed Generating Revenue
5. Grant 01-Feb-2019 00000 00.000 Completed Generating Revenue
4. Accelerator/Incubator 18-Mar-2018 00.000 Completed Generating Revenue
3. Later Stage VC 01-Jul-2016 00000 00.000 Completed Generating Revenue
2. Later Stage VC (Series A) 29-May-2015 $5.53M $7.03M 000.00 Completed Startup
1. Seed Round 21-Feb-2013 $1.5M $1.5M 00.00 Completed Startup
To view Sanguine’s complete valuation and funding history, request access »

Sanguine Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
To view Sanguine’s complete cap table history, request access »

Sanguine Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of personalized medicines intended to bridge the gap between patients and researchers. The company provides to
Other Healthcare Technology Systems
Woburn, MA
139 As of 2023
00.000
0000000000 0 00.000

0000 0

ore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation u
0000000000000
Oxford, United Kingdom
000 As of 0000
00000
0000 0000-00-00
00000000000 00000

000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. D
0000000000000 000000
Chicago, IL
0000 As of 0000
00.000
000000000 00 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Sanguine Competitors (10)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Evox Therapeutics Venture Capital-Backed Oxford, United Kingdom 000 00000 00000000000 00000
000000 Venture Capital-Backed Chicago, IL 0000 00.000 000000000 00 00.000
00000 000 Formerly VC-backed Cherry Hill, NJ 0 000.00 000000000 000.00
000000 00000000000 Venture Capital-Backed Ghent, Belgium 00 00000 00000000000 00000
0000000000 0000000 Formerly VC-backed Cambridge, MA 0000 00000 00000000000
You’re viewing 5 of 10 competitors. Get the full list »

Sanguine Executive Team (11)

Name Title Board Seat Contact Info
Brian Neman Co-Founder, Chief Executive Officer & Board Member
Christine Kelberman Chief Financial Officer
Gerald Lee Co-Founder & Chief Product Officer
Kaley Zeitouni Co-Founder & Vice President of Patient Relations
Donald Jones JD Advisor
You’re viewing 5 of 11 executive team members. Get the full list »

Sanguine Board Members (7)

Name Representing Role Since
Aaron Fisher BroadOak Capital Partners Board Member 000 0000
Benjamin Weiss Heliant Ventures Board Observer 000 0000
Brian Neman Sanguine Co-Founder, Chief Executive Officer & Board Member 000 0000
Marvin Yee Self Board Member 000 0000
Timothy Triche Ph.D Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Sanguine Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Sanguine Investors (20)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Albany Capital (Australia) Venture Capital Minority 000 0000 000000 0
BroadOak Capital Partners Growth/Expansion Minority 000 0000 000000 0
Vitamin Capital Venture Capital Minority 000 0000 000000 0
National Science Foundation Government 000 0000 000000 0
StartUp Health Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 20 investors. Get the full list »

Ready to get started?

Request a free trial